A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Carcinoma, Renal Cell Clinical Trial

Official title:

An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05899049
• Other study ID #: 6482-012 China Extension
• Secondary ID: MK-6482-012 Chin
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: July 27, 2022
• Est. completion date: December 1, 2026

Study information

• Verified date: June 2024
• Source: Merck Sharp & Dohme LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this China extension study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in Chinese participants with advanced clear cell renal cell carcinoma (ccRCC).

The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.

Description:

The China extension study will include participants previously enrolled in China in the global study for MK-6482-012 (NCT04736706) plus those enrolled during the China extension enrollment period. A total of approximately 249 Chinese participants will be enrolled.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 249
• Est. completion date: December 1, 2026
• Est. primary completion date: December 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Has histologically confirmed diagnosis of RCC with clear cell component.

• Has received no prior systemic therapy for advanced ccRCC

• Male participants are abstinent from heterosexual intercourse or agree to use contraception during and for at least 7 days after last dose of study intervention with belzutifan and lenvatinib.

• Female participants are not pregnant or breastfeeding and are either not a woman of child-bearing potential (WOCBP) or use a contraceptive method that is highly effective or are abstinent from heterosexual intercourse during the intervention period and for at least 120 days after pembrolizumab or pembrolizumab/quavonlimab or for at least 30 days after last dose of lenvatinib or belzutifan, whichever occurs last

• Has adequately controlled blood pressure with or without antihypertensive medications

• Has adequate organ function.

• Participants receiving bone resorptive therapy must have therapy initiated at least 2 weeks prior to randomization/allocation

Exclusion Criteria:

• Has a known additional malignancy that is progressing or has required active treatment within the past 3 years

• Has had major surgery, other than nephrectomy within 4 weeks prior to randomization

• Has known central nervous system (CNS) metastases and/or carcinomatous meningitis

• Has received prior radiotherapy within 2 weeks prior to first dose of study intervention

• Has hypoxia or requires intermittent supplemental oxygen or requires chronic supplemental oxygen

• Has clinically significant cardiac disease within 12 months from first dose of study intervention

• Has a history of interstitial lung disease

• Has symptomatic pleural effusion; a participant who is clinically stable following treatment of this condition is eligible

• Has preexisting gastrointestinal or non-gastrointestinal fistula

• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment

• Has a known psychiatric or substance abuse disorder that would interfere with requirements of the study

• Has received a live or live-attenuated vaccine within 30 days before the first dose of study drug; killed vaccines are allowed

• Has an active autoimmune disease that has required systemic treatment in the past 2 years

• Has a history of noninfectious pneumonitis that required steroids or has current pneumonitis

• Has an active infection requiring systemic therapy

• Has a known history of human immunodeficiency virus (HIV) infection

• Has a known history of Hepatitis B

• Has radiographic evidence of intratumoral cavitation, encasement or invasion of a major blood vessel

• Has clinically significant history of bleeding within 3 months prior to randomization

• Has had an allogenic tissue/solid organ transplant

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Renal Cell

Intervention

Biological:
• Pembrolizumab
Pembrolizumab 400 mg administered Q6W via IV infusion

Drug:
• Belzutifan
Belzutifan 120 mg administered QD via oral tablet

Biological:
• Pembrolizumab/Quavonlimab
Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion

Drug:
• Lenvatinib
Lenvatinib 20 mg administered QD via oral capsule

Locations

Country	Name	City	State
China	Beijing Cancer hospital-Renal carcinoma and melanoma ( Site 6000)	Beijing	Beijing
China	West China Hospital Sichuan University-Urology Surgery ( Site 6016)	Cheng Du	Sichuan
China	Chongqing University Cancer Hospital ( Site 6009)	Chongqing	Chongqing
China	Guangzhou First People's Hospital ( Site 6007)	Guangzhou	Guangdong
China	SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 6003)	Guangzhou	Guangdong
China	The First Affiliated Hospital of Guangzhou Medical University-Urology ( Site 6036)	Guangzhou	Guangdong
China	The First Affiliated Hospital, Zhejiang University ( Site 6024)	Hangzhou	Zhejiang
China	The First Hospital of Jiaxing ( Site 6033)	Jiaxing	Zhejiang
China	The First Affiliated Hospital of Nanchang University ( Site 6019)	Nanchang	Jiangxi
China	Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( S	Nanjing	Jiangsu
China	Ningbo First Hospital-Urology ( Site 6028)	Ningbo	Zhejiang
China	The Second Affiliated Hospital of Soochow University-Urology ( Site 6025)	Suzhou	Jiangsu
China	The Second Hospital of Tianjin Medical University ( Site 6032)	Tianjin	Tianjin
China	The First Affiliated Hospital of Wenzhou Medical University-Urology Surgery ( Site 6021)	Wenzhou	Zhejiang
China	Wuhan Union Hospital ( Site 6002)	Wuhan	Hubei
China	The First Affiliated Hospital of Xi'an Jiaotong University ( Site 6014)	Xi'an	Shaanxi
China	Henan Cancer Hospital-Urology ( Site 6006)	Zhengzhou	Henan

Sponsors (2)

Lead Sponsor	Collaborator
Merck Sharp & Dohme LLC	Eisai Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)	PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as =20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of =5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR based on RECIST 1.1 will be presented.	Up to approximately 58 months
Primary	Overall Survival (OS)	OS is defined as the time from randomization to death due to any cause.	Up to approximately 58 months
Secondary	Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR	ORR is defined as the percentage of participants who have a complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by BICR based on RECIST 1.1 will be presented.	Up to approximately 58 months
Secondary	Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR	For participants who demonstrate a confirmed CR (disappearance of all target lesions) or confirmed PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until PD or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of =5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by BICR based on RECIST 1.1 will be presented.	Up to approximately 58 months
Secondary	Number of Participants Who Experienced At least One Adverse Event (AE)	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience at least one AE will be presented.	Up to approximately 58 months
Secondary	Number of Participants Who Discontinue Study Treatment Due to an AE	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be presented.	Up to approximately 58 months

External Links

•   Merck Clinical Trials Information
•   Plain Language Summary